Portugal Joaquim Cunha, executive director of Health Cluster Portugal – a private, non-profit organisation dedicated to the consolidation of Portugal’s healthcare industry – discusses the up and coming changes to the healthcare sector through the innovative use of technology and its data. He also highlights why a new era for the…
Baltics In terms of being able to access medicines, patients in the Baltic states fare poorly compared to many of their European counterparts. 135 new medicines were approved by regulators in Lithuania and Estonia in 2016, but only 38 and 30 were made available to patients respectively. Latvia fares even worse,…
UK Terry O’Regan, VP and managing director at Biogen UK and Ireland, discusses the company’s longstanding commitment to the UK, market access issues, and why Biogen is staying the course with developing Alzheimer’s products at a time when many MNCs are winding down their neurology programs. How would you describe Biogen’s…
UK Sir John Savill, chief executive of the Medical Research Council between 2010 and 2018, discusses the organization’s transition into part of the new UK Research and Innovation (UKRI) grouping, the highlights of his tenure in terms of medical research in the UK, and the potential pitfalls of the Brexit process.…
UK Steve Ford, CEO of Parkinson’s UK, one of the UK’s leading research-based charities, discusses his organization’s recent Digital Leadership Award, presenting the needs of Parkinson’s patients to stakeholders, and why the UK will remain a leading research hub in the years to come. One of our key challenges is…
UK Tony Jones, CEO of One Nucleus, a life sciences membership organization centered on the Greater London-Cambridge-East of England corridor, discusses the role of SMEs within the UK’s healthcare ecosystem, translational research, and how the association’s members will navigate the post-Brexit landscape in the UK. One Nucleus, which was established in…
UK Lord O’Shaughnessy, parliamentary under secretary of state for health in the UK, discusses how stakeholders are interacting to ensure that the UK remains at the forefront of the global life sciences industry post-Brexit. We have scrutinized the Life Sciences Industrial Strategy and found it to be a very optimistic…
UK Aisling Burnand, CEO of the Association of Medical Research Charities (AMRC), shares the organization’s vision and the significant contributions of its member charities to the life sciences R&D ecosystem in the UK. She also outlines some of the main trends within the sector including digitalization and new models of fundraising,…
Poland Arjo, formerly Arjo Huntleigh, has undergone a rebrand and established its first formal office in Poland in 2017. Konrad Pianko, president of the CEE region which includes over 22 countries, intends to capitalize on the growth potential in the Polish market, bring innovative rental solutions to the hospital and healthcare…
UK Michelle Mitchell, CEO of the Multiple Sclerosis Society in the UK since 2013, discusses her charity’s aims; their focus on research and development; funding in the face of Brexit; and policy changes in the future. Although the MS community is fairly small, the science is telling us that with…
Portugal ARSLVT exists to make sure that people living in the Lisbon and Tagus Valley have access to quality health care, adapting the resources available to the region’s health needs and complying with and enforcing the National Health Plan. Luis Pisco is confident in Portugal’s development as a healthy nation, and…
Baltics As the Lithuanian market matures, profound shifts have been taking place in the arena of human resources and how drug developers go about identifying, acquiring and retaining the personnel they require for a new age of medical science. “There are a number of emerging trends underway that are forcing companies…
See our Cookie Privacy Policy Here